Industrialisation and standardisation of MS-based proteomics

Mass spectrometry (MS)-based proteomics methods are becoming increasingly important in the research and production of modern biotherapeutics thanks to rapid developments in instrumentation. Their widespread use in the pharmaceutical industry and in clinical trials is currently still hampered by a lack of user-friendliness, robustness and standardisation as well as high costs.

By bringing together developers and users of MS-based proteomics, innovative solutions are to be created along the value chain from sample preparation to instrumentation and data analysis.

The aim is to significantly reduce the costs of MS-based proteome and protein analytics as a prerequisite for the standardised use of the technologies in the pharmaceutical industry and in clinics. The network is dedicated to the automation of the entire process chain, the establishment of robust pipelines in quality control and assurance, and the use of new, AI-based methods for improved interpretation of MS data.


  • Drug discovery
  • Biomarker discovery
  • Elucidation of target and off-target effects
  • Companion Diagnostics
  • Cancer diagnostics


  • Standardised workflow from sample to result
  • Easy handling even for non-experts
  • Automated process chains, including highly automated sample preparation
  • Use of new AI-based methods for faster evaluation and extraction of more and new information from MS datasets
  • Increased throughput and reduced time for proteomic analysis
  • Cost reduction of proteomic analytics

Our network